Policy / Pricing The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMs Drug ChannelsBy Adam J.Read full story pharminent June 2, 2026 (Last updated: June 4, 2026) Drug Channels By Adam J. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancerNext: Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb Related Stories Policy / Pricing The next FDA commissioner must be a champion for gene therapies pharminent June 5, 2026 Policy / Pricing Stakeholders want Makary’s voucher program paused, call for FDA independence pharminent June 5, 2026 Policy / Pricing SCOTUS backs generic firm Hikma in skinny label dispute pharminent June 4, 2026
